1038925-00-6 Usage
Description
(3S,5S)-5-biphenyl-4-ylmethyl-3-methylpyrrolidin-2-one is a chiral organic compound with a unique molecular structure, featuring a pyrrolidin-2-one core and a biphenyl-4-ylmethyl group attached to the 5-position. (3S,5S)-5-biphenyl-4-ylmethyl-3-methylpyrrolidin-2-one exhibits two stereocenters at the 3 and 5 positions, with the (3S,5S) configuration indicating the specific arrangement of the substituents. (3S,5S)-5-biphenyl-4-ylmethyl-3-methylpyrrolidin-2-one is of interest in the field of pharmaceutical chemistry due to its potential as a building block or intermediate in the synthesis of biologically active molecules.
Uses
Used in Pharmaceutical Industry:
(3S,5S)-5-biphenyl-4-ylmethyl-3-methylpyrrolidin-2-one is used as a chiral intermediate for the synthesis of various pharmaceutical compounds. Its unique structure and stereochemistry make it a valuable component in the development of new drugs with improved efficacy and selectivity.
Used in Sacubitril Impurity Analysis:
(3S,5S)-5-biphenyl-4-ylmethyl-3-methylpyrrolidin-2-one is identified as an impurity of Sacubitril (S080895), an antihypertensive drug used in combination with valsartan. It is important to monitor and control the presence of this impurity in the final drug product to ensure safety, efficacy, and quality.
Check Digit Verification of cas no
The CAS Registry Mumber 1038925-00-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,3,8,9,2 and 5 respectively; the second part has 2 digits, 0 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1038925-00:
(9*1)+(8*0)+(7*3)+(6*8)+(5*9)+(4*2)+(3*5)+(2*0)+(1*0)=146
146 % 10 = 6
So 1038925-00-6 is a valid CAS Registry Number.
1038925-00-6Relevant articles and documents
NEW PROCESSES
-
Page/Page column 300, (2009/08/16)
The invention relates to a new process for producing NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a γ-amino-δ-biphenyl-α-methylalkanoic acid, or acid ester, backbone. In detail, the new processes, according to the present invention, are ultimately related to the synthesis of intermediates to prepare the above NEP inhibitors, namely compounds according to formula (1), or salt thereof, wherein R1 and R2 are, independently of each other, hydrogen or a nitrogen protecting group, and R3 is a carboxyl group or an ester group, preferably carboxyl group or alkyl ester.
